How to Get Alprostadil (Caverject/MUSE) in North Dakota

What Alprostadil Is and Why It Is Prescribed

Alprostadil is a synthetic prostaglandin E1 that relaxes smooth muscle in penile arterial walls, producing an erection in men with erectile dysfunction (ED) that has not responded to oral phosphodiesterase-5 inhibitors such as sildenafil or tadalafil. The drug is prescription-only in the United States and is sold under two FDA-approved brand formats: Caverject (and Caverject Impulse), which are injected directly into the corpus cavernosum, and MUSE, a small medicated pellet placed into the urethra [1].

The 1996 landmark trial by Linet and Ogrinc (N=683) published in the New England Journal of Medicine demonstrated that intracavernosal alprostadil produced satisfactory erections in 94% of injections compared with 9% for placebo (P<0.001), establishing the drug's efficacy for refractory ED [2]. That evidence base has not been seriously challenged in the three decades since.

Alprostadil works within 5 to 20 minutes of administration. Erections typically last 30 to 60 minutes. Because the mechanism bypasses central and peripheral nerve pathways, alprostadil is effective even in men with spinal cord injury, radical prostatectomy, or severe vascular disease, populations for whom oral agents frequently fail [3].

North Dakota Prescribing Authority: Who Can Write the Prescription

In North Dakota, alprostadil may be prescribed by any licensed prescriber with authority to prescribe Schedule V or unscheduled legend drugs. That includes medical doctors (MD), doctors of osteopathic medicine (DO), physician assistants (PA-C), and nurse practitioners (NP/APRN). North Dakota law grants full prescriptive authority to Advanced Practice Registered Nurses operating under a collaborative practice agreement with a physician, per North Dakota Century Code §43-12.1 [4]. Physicians and PAs need no such agreement to prescribe independently.

Most alprostadil prescriptions in North Dakota originate with urologists, but primary care physicians and internal medicine specialists write them routinely. Men who cannot access an in-person specialist in the state's rural counties, including much of the Missouri Slope, Red River Valley farmland, and the western Badlands region, frequently turn to telehealth for their initial consultation.

Prescribers must conduct a clinical evaluation before issuing an alprostadil prescription. That evaluation includes a sexual health history, a review of cardiac risk, a blood pressure reading, and confirmation that phosphodiesterase-5 inhibitors have been tried and failed or are contraindicated. The American Urological Association's 2018 Erectile Dysfunction Guideline (updated 2024) supports second-line use of intracavernosal alprostadil when oral therapy is insufficient [5].

Telehealth Access to Alprostadil in North Dakota

North Dakota law explicitly permits telehealth prescribing for legend drugs, including alprostadil, provided the prescriber establishes a valid patient-provider relationship through a synchronous audio-video encounter. A text-only or asynchronous questionnaire alone does not meet the standard under North Dakota Admin Code Article 33.1-10 [4].

HealthRX conducts synchronous video visits and can issue alprostadil prescriptions for North Dakota residents who meet clinical criteria. The visit typically covers sexual health history, current medications, cardiovascular status, and any prior ED treatment. No in-person physical exam is required for the telehealth consultation itself, though the first injection of Caverject must be performed in a clinical or supervised setting per FDA labeling [1].

Telehealth prescribing for ED medications expanded substantially after the 2020 Public Health Emergency flexibilities and has remained available in North Dakota since. The FDA's guidance on establishing a valid prescribing relationship, referenced in its 2023 telemedicine framework, permits prescribing of non-controlled legend drugs including alprostadil via telemedicine when a synchronous visit is conducted [6].

Several national telehealth platforms list North Dakota as a covered state for ED prescribing. Response times vary, but most patients receive a prescription decision within 24 to 48 hours of completing their video visit.

Required Labs and Medical Workup Before Starting Alprostadil

A baseline lab panel is not strictly mandated by the FDA labeling for alprostadil, but clinical guidelines from the American Urological Association and the Endocrine Society recommend checking fasting glucose, HbA1c, and total testosterone before initiating any ED therapy, because undiagnosed diabetes and hypogonadism are among the most common reversible contributors to ED [5][7].

The Endocrine Society's 2018 guideline on testosterone therapy states that testosterone deficiency should be ruled out before attributing ED solely to vascular causes, since testosterone replacement alone sometimes restores erectile function in hypogonadal men and may improve alprostadil response when used concurrently [7]. A standard pre-treatment panel at HealthRX includes:

• Fasting glucose and HbA1c
• Total testosterone (morning draw, two readings if borderline)
• Complete blood count to screen for hematologic contraindications
• Blood pressure at the time of the visit (via patient self-report or pharmacy cuff)
• Lipid panel if cardiovascular risk has not been assessed in the prior 12 months

Men with cardiovascular disease require additional caution. The Princeton III Consensus Conference (2012) established graded cardiac risk criteria for sexual activity and ED pharmacotherapy [8]. Alprostadil does not carry the nitrate-interaction risk that phosphodiesterase-5 inhibitors do, but significant hypotension is possible, particularly at higher doses, so blood pressure documentation is essential [1][8].

Dosing: Caverject vs. MUSE

Caverject (alprostadil sterile powder for injection) is reconstituted and injected into the lateral aspect of the proximal third of the penis. The FDA-approved starting dose is 1.25 mcg, titrated upward in-office to achieve an erection lasting no more than 60 minutes. Most men require 5 to 20 mcg per dose. The maximum recommended dose is 60 mcg, and injections should not be given more than 3 times per week with at least 24 hours between doses [1].

MUSE (alprostadil urethral suppository) delivers 125, 250, 500, or 1 to 000 mcg pellets. The drug is absorbed through the urethral mucosa into the corpus spongiosum. Efficacy is lower than intracavernosal injection: a key MUSE trial found that 65% of at-home administrations produced an erection sufficient for intercourse compared with 19% for placebo [9]. The lower bioavailability makes MUSE a preferred option for men who cannot or will not self-inject.

Priapism, defined as an erection lasting more than 4 hours, occurs in approximately 1% of Caverject users and represents a urologic emergency. Patients must be counseled to seek emergency care immediately if this occurs. Penile fibrosis has been reported in up to 7.8% of long-term Caverject users [1][2].

Pharmacies in North Dakota That Dispense Alprostadil

Brand-name Caverject and MUSE are dispensed by retail and specialty pharmacies. National chains including Walgreens and CVS carry or can order the brand products, though stock varies by location. North Dakota has compounding pharmacies operating under 503A of the Federal Food, Drug, and Cosmetic Act, which permits patient-specific compounding of alprostadil at concentrations not commercially available [10].

503A compounding pharmacies may prepare alprostadil at custom concentrations, frequently combined with vasoactive agents such as papaverine or phentolamine in bi-mix or tri-mix formulations. These compound preparations are not FDA-approved products but are legal when dispensed pursuant to a valid patient-specific prescription from a licensed prescriber [10]. The North Dakota State Board of Pharmacy oversees 503A compounders operating within the state and requires them to meet USP <797> sterile compounding standards [4].

For patients who prefer mail-order dispensing, HealthRX works with accredited 503A pharmacies that ship temperature-controlled alprostadil preparations directly to North Dakota addresses. Shipping typically takes 3 to 5 business days after prescription verification.

The FDA's current compounding policy, outlined in its 503A guidance documents, prohibits 503A pharmacies from compounding copies of commercially available drugs unless there is a documented clinical difference. Prescribers ordering compounded alprostadil typically document a need for a custom concentration or a combined formulation to satisfy this requirement [10].

Cost and Insurance Coverage in North Dakota

Brand-name Caverject costs approximately $60 to $90 per single-use vial at retail without insurance. A six-dose kit runs $350 to $500 at North Dakota pharmacies. MUSE suppositories cost roughly $50 to $100 per unit at standard retail. Compounded alprostadil from a 503A pharmacy can be substantially less expensive, often $30 to $60 per vial for a comparable dose.

North Dakota Medicaid does not cover alprostadil for erectile dysfunction as of 2025. This aligns with a broad pattern: a 2020 analysis in the Journal of Sexual Medicine found that fewer than 30% of state Medicaid programs covered any injectable ED therapy [11].

Private insurance coverage varies by plan. When coverage exists, prior authorization is typically required. Prior authorization documentation generally includes:

• A confirmed diagnosis of erectile dysfunction (ICD-10 code N52.x)
• Documentation that at least two different oral PDE5 inhibitors were tried and failed or are contraindicated
• A prescriber attestation that alprostadil is medically necessary
• Recent lab results if requested by the plan

Medicare Part D covers Caverject and MUSE only when prescribed for a covered indication other than ED, such as diagnosis of penile fibrosis or Peyronie's disease in some cases. Standard ED is explicitly excluded from Medicare Part D coverage under 42 U.S.C. §1395w-102(e)(2) [12].

Manufacturer savings programs have historically offered discounts on Caverject for commercially insured patients. Pfizer's patient assistance programs may reduce out-of-pocket costs for eligible individuals. Patients should verify current program availability directly with the manufacturer.

Transferring an Existing Alprostadil Prescription to North Dakota

If you have an existing alprostadil prescription from another state, you may transfer it to a North Dakota pharmacy provided the prescription has remaining refills and the prescriber is licensed to prescribe in the state where the prescription was written. North Dakota follows the National Association of Boards of Pharmacy Model Rules on prescription transfers for non-controlled substances, which permit a single transfer between pharmacies unless the original pharmacy is within the same chain [4].

If your original prescriber is not licensed in North Dakota, a new prescription from a North Dakota-licensed provider is required. A telehealth visit with HealthRX satisfies this requirement, and an existing medical record from your prior provider can be used to shorten the clinical intake process.

Alprostadil is not a federally controlled substance under the DEA Controlled Substances Act, so the transfer restrictions that apply to Schedule II through V drugs do not govern alprostadil transfers [13].

Timeline: From Consultation to First Dose

For most North Dakota patients using the HealthRX telehealth pathway, the timeline runs as follows. A synchronous video visit is scheduled and completed, typically within 24 to 48 hours of sign-up. If clinical criteria are met, a prescription is sent electronically to the patient's pharmacy of choice or to a partnered 503A compounder the same day. Retail pharmacy dispensing occurs within 24 hours for in-stock products. Compounded preparations ship within 2 to 4 business days and arrive within 3 to 5 additional days, for a total of 5 to 9 days from consultation to delivery in most North Dakota zip codes.

Before self-administering Caverject at home, the FDA requires that the first injection be given under clinical supervision so that dose titration can occur and the patient can demonstrate proper injection technique [1]. This supervised administration may be arranged with a local urologist, primary care physician, or, in some cases, via a partnered clinic in a nearby North Dakota city such as Fargo, Bismarck, Grand Forks, or Minot. MUSE does not carry the same mandatory in-office first-dose requirement, making it a faster path to home use for patients in remote areas.

Special Populations: Post-Prostatectomy and Neurogenic ED

Alprostadil has a well-established role in penile rehabilitation after radical prostatectomy. A 2009 randomized controlled trial (N=212) published in the Journal of Urology found that early use of intracavernosal alprostadil after nerve-sparing prostatectomy supported return of spontaneous erectile function at 18 months compared with on-demand use alone [14]. The American Urological Association's prostate cancer survivorship guidance supports offering vasoactive injection therapy as part of post-prostatectomy sexual rehabilitation [5].

For men with spinal cord injury, alprostadil is effective regardless of the level or completeness of injury because its mechanism does not depend on intact neural pathways. A Cochrane review covering 5 randomized trials found intracavernosal prostaglandin E1 superior to placebo for neurogenic ED with a relative risk of achieving erection of 3.72 (95% CI 2.49 to 5.55) [15].

North Dakota's Veterans Affairs facilities in Fargo and the VA outpatient clinics in Bismarck and Minot may cover alprostadil for eligible veterans as part of the VA Formulary, which does include prostaglandin E1 agents for erectile dysfunction in service-connected conditions. Veterans should confirm current formulary status with their VA prescriber.

Safety, Contraindications, and Monitoring

Alprostadil is contraindicated in men with hypersensitivity to prostaglandin E1, men with conditions predisposing them to priapism (including sickle cell anemia, sickle cell trait, multiple myeloma, or leukemia), and men with penile anatomical deformities that would make injection technically hazardous [1]. The FDA label also lists Peyronie's disease as a relative contraindication for intracavernosal injection due to fibrosis risk.

Pain at the injection site is the most common adverse effect, reported in 29 to 37% of patients in clinical trials [2]. Hypotension and dizziness occur in roughly 3% of users. Urethral burning affects approximately 12% of MUSE users [9]. All patients should be instructed on how to recognize priapism (rigid erection persisting beyond 4 hours without sexual stimulation) and must have a plan for emergency evaluation, which in North Dakota means the nearest emergency department.

Ongoing monitoring for men on long-term alprostadil includes a penile examination every 3 to 6 months to assess for nodule formation or early fibrosis, dose reassessment if efficacy declines, and periodic cardiovascular risk review consistent with the Princeton III criteria [8]. The American Urological Association recommends against using alprostadil more than 3 times per week [5].